Management of community-associated methicillin-resistant Staphylococcus aureus skin abscesses in children

The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.

Skin abscesses in previously well children are primarily due to methicillin-susceptible Staphylococcus aureus (MSSA). However, recently, community-associated methicillin-­resistant S aureus (CA-MRSA) has become a common cause of skin abscesses. This type of S aureus is resistant to all beta-lactam antibiotics including penicillins and cephalosporins. Preliminary data from the Canadian Paediatric Surveillance Program show that CA-MRSA infections occur all across Canada (Nicole Le Saux, personal communication). Children of all ages, including neonates, can become infected with MRSA. Clinical distinction between MSSA and MRSA causing an abscess is not possible, but in one study, over one-half of abscesses due to CA-MRSA were on the buttocks and lower limbs [1]. Discharge or pus from an infected skin abscess should always be sent for culture because it is the only way to reliably identify MRSA. Recurrences are very common. Epidemiological risk factors associated with the spread of CA-MRSA in the child or family include close ­skin-to-skin contact, openings in the skin such as cuts or abrasions, contaminated items and surfaces, crowded living conditions and poor hygiene. Clusters or increased rates have been reported in Aboriginal populations, athletes, daycare attendees, military recruits, intravenous drug users, men who have sex with men, and prisoners, but many infected children have no risk factors.

Until CA-MRSA became a problem, drainage alone was the accepted therapy for uncomplicated skin abscesses [1]. Similar to MSSA, CA-MRSA can cause osteomyelitis, septic arthritis, necrotizing fasciitis, sepsis and pneumonia (especially following influenza), so concern has been expressed that CA-MRSA abscesses could progress to invasive disease if not treated with oral antibiotics [2], especially in neonates. However, the only paediatric randomized trial in the CA-MRSA era did not describe any of these complications, and showed equivalent cure rates at 10 days with ­trimethoprim/sulfamethoxazole (TMP/SMX) versus placebo post­drainage with more recurrences at the 10-day but not at the 30-day follow-up in the placebo group [1]. Therefore, most children can be managed initially with drainage alone (Table 1). Patients must be reassessed if they develop systemic symptoms, have worsening local symptoms or have demonstrated no improvement after 48 h. However, empirical oral or parenteral antibiotics should be used from the day of presentation if the child is younger than three months of age, or has significant associated cellulitis, fever or other systemic signs of illness.

In the limited situations in which one chooses to use antibiotics for a skin abscess postdrainage, TMP/SMX covers almost 100% of MSSA and CA-MRSA, and is generally well tolerated. There are concerns regarding the use of TMP/SMX in serious infections because penetration into pus, lungs and thick-walled abscesses is poor, and S aureus may produce sufficient thymidine to inactivate the drug [3]. However, these concerns do not preclude its use for an uncomplicated skin abscess. Doxycycline is a good option for children eight years of age or older who can swallow pills. Another option is clindamycin, but an increasing percentage of CA-MRSA isolates are resistant, the suspension is unpalatable and this drug increases the risk of Clostridium difficile colitis to a greater extent than does TMP/SMX. Increasing resistance is also a problem for fluoroquinolones including ciprofloxacin. An oral agent that would cover most CA-MRSA is linezolid, but this drug is prohibitively expensive and is not advised for uncomplicated skin abscesses.

One limitation of TMP/SMX is poor coverage for group A streptococcus, but this organism is a rare cause of skin abscesses, and abscesses due to this organism are likely to resolve postdrainage with no adjunctive antibiotics. However, in the setting of significant cellulitis with a skin abscess for which one wants to cover group A streptococcus, MSSA and MRSA, an option appropriate for outpatients is to add a second antibiotic (typically cephalexin) to TMP/SMX pending cultures. For skin infections other than abscesses, beta-lactams remain appropriate therapy in most circumstances, although the local prevalence of CA-MRSA, the severity of illness and patient comorbidities must be taken into account.

Parents are often very concerned when they are told that their child has been infected with this ‘superbug’. Excellent parent handouts are available online.

Decolonization is not usually advised because failure is common even with multiple interventions involving the child and family members.

Conclusion

The vast majority of skin abscesses resolve postdrainage without antibiotics. However, clinicians may choose to start antibiotics pending culture, especially in infants younger than three months of age, or in children with serious medical problems, signs of systemic illness or significant surrounding cellulitis.

Acknowledgements

The Canadian Paediatric Society thanks Drs James Irvine (Member) and Sam Wong (Chair), who reviewed this Practice Point on behalf of the First Nations, Inuit and Métis Health Committee.

INFECTIOUS DISEASES AND IMMUNIZATION COMMITTEE

Members: Robert Bortolussi MD (chair); Jane Finlay MD; Susanna Martin MD (board representative); Jane C McDonald MD; Heather Onyett MD; Joan L Robinson MD
Liaisons: Upton D Allen MD, Canadian Pediatric AIDS Research Group; Janet Dollin MD, College of Family Physicians of Canada; Charles PS Hui MD, CPS Liaison to Health Canada, Committee to Advise on Tropical Medicine and Travel; Nicole Le Saux MD, Canadian Immunization Monitoring Program, ACTive; Larry Pickering MD, American Academy of Pediatrics, Committee on Infectious Diseases; Marina I Salvadori MD, CPS Liaison to Health Canada, National Advisory Committee on Immunization; John Spika MD, Public Health Agency of Canada
Consultants: James Kellner MD; Noni E MacDonald MD; Dorothy Moore MD
Principal authors: Joan L Robinson MD; Marina I Salvadori MD

References

Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.